When to Discontinue FIT Screening for Colorectal Cancer

Age‑Based Stopping Criteria

Routine FIT screening should be stopped at age 75 for individuals who have an adequate history of prior negative tests (e.g., recent high‑quality colonoscopy or consecutive negative FITs). This reflects a weak recommendation based on low‑quality evidence and is endorsed by the U.S. Multi‑Society Task Force and the American College of Physicians. 1
Between ages 76 and 85, FIT screening may be offered only to patients who have never been screened before, after a comprehensive assessment of overall health, comorbidities, and ability to tolerate colonoscopy and cancer treatment. This selective approach is a qualified recommendation from the American Cancer Society. 2
After age 85, FIT screening should be discontinued for all patients regardless of prior screening history because procedure‑related harms and competing mortality risks outweigh any potential mortality benefit. This is a qualified recommendation from the American Cancer Society. 2

Screening should be stopped when an individual’s estimated life expectancy falls below 10 years, irrespective of chronological age. The 10‑year threshold reflects the time required for FIT screening to achieve a mortality benefit in colorectal cancer. This is a weak recommendation with low‑quality evidence from the U.S. Multi‑Society Task Force and the American College of Physicians. 1
Comorbidity burden should be evaluated with validated indices (e.g., Charlson Comorbidity Index) or clinical judgment to determine whether the patient could safely undergo diagnostic colonoscopy and subsequent cancer treatment if a FIT result is positive. This assessment is recommended by the American Cancer Society. 2

Patients who have had a high‑quality colonoscopy with a negative result within the past 10 years have the strongest justification for stopping FIT screening at age 75, because colonoscopy provides durable protection against colorectal cancer. This is a weak recommendation with low‑quality evidence from the U.S. Multi‑Society Task Force and the American College of Physicians. 1
Never‑screened individuals may continue FIT screening up to age 85, as they lack the protective benefit of prior negative tests and have a higher baseline risk of colorectal cancer. This recommendation is supported by the American Cancer Society. 3

Do not continue FIT screening beyond age 75 in patients who have been adequately screened previously, even if they appear “healthy for their age.” Evidence shows no additional benefit and a higher risk of harm; this is a weak recommendation from the U.S. Multi‑Society Task Force. 1
Do not initiate FIT screening in patients older than 75 who have already undergone prior screening, as the benefit‑to‑harm ratio is unfavorable. This guidance comes from the American Cancer Society. 2
Do not rely solely on life‑expectancy calculators; integrate comorbidity assessment, functional status, and patient preferences into the decision‑making process. This is a qualified recommendation from the American Cancer Society. 3

The recommendation to stop FIT screening at age 75 carries a weak recommendation with low‑quality evidence across major guideline bodies (U.S. Multi‑Society Task Force, American College of Physicians, American Cancer Society). The evidence base consists mainly of microsimulation modeling studies rather than randomized trials in older adults. 1
Despite the weak evidence grade, there is strong consensus among guideline societies that harms outweigh benefits beyond age 75 in adequately screened populations. 1

The American Cancer Society recommends starting screening at age 45 years for all average-risk adults, though the strongest evidence supports screening from age 50 onward (strong recommendation) 4, 5, 6
The American Gastroenterological Association recommends stopping screening at age 75 years in patients who are up-to-date with prior screening and have negative results, particularly if they have had high-quality colonoscopy or life expectancy is less than 10 years 4, 5, 6
For ages 76-85 years, the American College of Physicians recommends offering screening only to those who have never been screened previously, considering their overall health status, comorbidities, and whether they are healthy enough to undergo treatment if cancer is detected 5, 6, 7
The American Cancer Society recommends discontinuing screening after age 85 years regardless of prior screening history, as harms outweigh benefits in this population 4, 8

The American Cancer Society classifies Cologuard as a second-tier screening test behind colonoscopy every 10 years and annual FIT, which are the cornerstones of screening and recommended as first-tier options 4
The screening interval for Cologuard is every 3 years when used as the primary screening modality, as recommended by the American Cancer Society 4
All positive Cologuard results mandate timely diagnostic colonoscopy as part of the screening process, according to the American Cancer Society 4, 8, 9

Cologuard is appropriate only for average-risk individuals, defined as those without family history of colorectal cancer, long-standing inflammatory bowel disease, genetic syndromes, or personal history of colorectal cancer or adenomatous polyps, as stated by the American College of Physicians 7, 10
The American College of Physicians recommends never using Cologuard in symptomatic patients with alarm symptoms, including rectal bleeding, narrowed stools, or unexplained weight loss, as these patients require immediate diagnostic colonoscopy regardless of any stool test results 9
Assess life expectancy before initiating screening, and avoid screening if life expectancy is less than 10 years due to comorbidities, as recommended by the American College of Physicians 7, 8

When offering multiple screening options, present colonoscopy every 10 years and annual FIT as the preferred choices, with Cologuard every 3 years as an acceptable alternative for patients who decline the first-tier tests, according to the American Cancer Society 4

Do not continue screening past age 75 years in patients with adequate prior negative screening history, as harms increasingly outweigh benefits with advancing age, as recommended by the American Cancer Society 4, 8, 9
Do not use Cologuard as a diagnostic test in patients with symptoms or known colorectal pathology, as it is a screening tool only for asymptomatic average-risk individuals, according to the American College of Physicians 9
Ensure colonoscopy capacity exists before ordering Cologuard, as positive results require diagnostic colonoscopy follow-up and failure to complete this workup renders the screening program ineffective, as stated by the American College of Physicians 9